(AOF) – Transgene announces the appointment of James Wentworth to the position of director of business development (chief business officer). This biotechnology company, which designs and develops immunotherapies against cancer based on viral vectors, specifies that it will be in charge of the definition, supervision and implementation of the business development strategy, commercial affairs , as well as the partnership strategy. Since 2022, he has managed business development at Adaptimmune, a biotech specializing in cell therapies based on T cell receptors.
Holder of a BSc and a PhD in Pharmacology from the University of Bristol as well as an MBA from the International Institute for Management Development (IMD) in Lausanne, James Wentworth has also worked for biotechnology companies in development stage as inVentiv Health (now Syneos Health), or Shire, and managed commercial launches in European markets for ViroPharma Europe.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
